Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Geneviève I.C.G. Ector, Inge G. P. Geelen, Avinash G. Dinmohamed, Mels Hoogendoorn, Peter E. Westerweel, Rosella P.M.G. Hermens & Nicole M.A. Blijlevens. (2023) Adherence to quality indicators in chronic myeloid leukemia care: results from a population-based study in The Netherlands. Leukemia & Lymphoma 64:2, pages 424-432.
Read now
Read now
Elias J. Jabbour, Lisa R. Siegartel, Jay Lin, Melissa Lingohr-Smith, Brandy Menges & Dinara Makenbaeva. (2019) Impact of earlier versus later monitoring on disease progression and healthcare costs among patients with chronic myeloid leukemia in the United States. Leukemia & Lymphoma 60:3, pages 668-674.
Read now
Read now
Guangying Sheng, Suning Chen, Ri Zhang, Miao Miao, Depei Wu, Seng Chuen Tan, Chao Liu & Tengbin Xiong. (2017) The impact of medical insurance coverage and molecular monitoring frequency on outcomes in chronic myeloid leukemia: real-world evidence in China. Journal of Medical Economics 20:4, pages 382-387.
Read now
Read now
Ranjana Arora & Richard D. Press. (2017) Measurement of BCR-ABL1 transcripts on the International Scale in the United States: current status and best practices. Leukemia & Lymphoma 58:1, pages 8-16.
Read now
Read now
Patricia Kropf, Gisoo Barnes, Boxiong Tang, Ashutosh Pathak & Jean-Pierre J. Issa. (2016) Healthcare utilization and costs associated with tyrosine kinase inhibitor switching in patients with chronic myeloid leukemia. Leukemia & Lymphoma 57:4, pages 935-941.
Read now
Read now
Annie Guérin, Lei Chen, Katherine Dea, Eric Q. Wu & Stuart L. Goldberg. (2014) Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. Current Medical Research and Opinion 30:7, pages 1345-1352.
Read now
Read now
Articles from other publishers (12)
Fang Cheng, Zheng Cui, Qiang Li, Liu Wang & Weiming Li. (2023) Adherence to tyrosine kinase inhibitor and clinical outcomes in patients with chronic myeloid leukemia. International Immunopharmacology 124, pages 110847.
Crossref
Crossref
Lynn Verweij, Geneviève I. C. G. Ector, Yolba Smit, Bas van Vlijmen, Bert A. van der Reijden, Rosella P. M. G. Hermens & Nicole M. A. Blijlevens. (2023) Effectiveness of digital care platform CMyLife for patients with chronic myeloid leukemia: results of a patient-preference trial. BMC Health Services Research 23:1.
Crossref
Crossref
Martin Vu, Koen Degeling, Ella R. Thompson, Piers Blombery, David Westerman & Maarten J. IJzerman. (2022) Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review. European Journal of Haematology 108:6, pages 469-485.
Crossref
Crossref
Vikalp Kumar Maheshwari, Cassandra Slader, Nidhi Dani, Christina Gkitzia, Quan Yuan, Tengbin Xiong, Yu Liu & Ricardo Viana. (2021) Enabling access to molecular monitoring for chronic myeloid leukemia patients is cost effective in China. PLOS ONE 16:10, pages e0259076.
Crossref
Crossref
Katia B. Pagnano, Ana Ines Varela, Carolina Pavlovsky, Israel Bendit, Vaneuza A. M. Funke & Virginia Abello Polo. (2021) Challenges in Chronic Myeloid Leukemia Management in South America. Current Hematologic Malignancy Reports 16:5, pages 440-447.
Crossref
Crossref
Susan Branford, Naranie Shanmuganathan & Timothy P. Hughes. 2021. Chronic Myeloid Leukemia. Chronic Myeloid Leukemia
245
264
.
Kibum Kim, Gwendolyn A. McMillin, Philip S. Bernard, Srinivas Tantravahi, Brandon S. Walker & Robert L. Schmidt. (2019) Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia. PLOS ONE 14:12, pages e0226552.
Crossref
Crossref
Michael Lauseker, Roman Gerlach, Wenke Worseg, Torsten Haferlach, Martin Tauscher, Joerg Hasford & Verena S. Hoffmann. (2019) Differences in treatment and monitoring of chronic myeloid leukemia with regard to age, but not sex: Results from a population‐based study. European Journal of Haematology 103:4, pages 362-369.
Crossref
Crossref
Dominick Latremouille-Viau, Annie Guerin, Patrick Gagnon-Sanschagrin, Katherine Dea, Benjamin G. Cohen & George J. Joseph. (2017) Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency. Journal of Managed Care & Specialty Pharmacy 23:2, pages 214-224.
Crossref
Crossref
William V. Padula, Richard A. Larson, Stacie B. Dusetzina, Jane F. Apperley, Rudiger Hehlmann, Michele Baccarani, Ekkehard Eigendorff, Joelle Guilhot, Francois Guilhot, Rudiger Hehlmann, Francois-Xavier Mahon, Giovanni Martinelli, Jiri Mayer, Martin C. Müller, Dietger Niederwieser, Susanne Saussele, Charles A. Schiffer, Richard T. Silver, Bengt Simonsson & Rena M. Conti. (2016) Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. Journal of the National Cancer Institute 108:7, pages djw003.
Crossref
Crossref
Qian Jiang & Robert Peter Gale. (2016) Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China. Journal of Cancer Research and Clinical Oncology 142:7, pages 1549-1555.
Crossref
Crossref
Stuart L. Goldberg, Luke P. Akard, Michael J. Dugan, Stefan Faderl & Andrew L. Pecora. (2015) Barriers to Physician Adherence to Evidence-Based Monitoring Guidelines in Chronic Myelogenous Leukemia. Journal of Oncology Practice 11:3, pages e398-e404.
Crossref
Crossref